Metoclopramide Hameln (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone, reducing the signal that initiates nausea and vomiting. In the gastrointestinal tract, the same blockade increases acetylcholine release, which stimulates coordinated muscle contractions and speeds gastric emptying.

The specific dose of Metoclopramide Hameln is determined by the prescribing clinician based on the patient’s condition, age, weight, renal and hepatic function, and the intended route of administration. Only a qualified health professional should set the dosing regimen.

Safety data for Metoclopramide Hameln in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified health professional after a thorough risk assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Metoclopramide differs from many antiemetics such as 5‑HT3 antagonists because it primarily blocks dopamine D2 receptors and also has pro‑kinetic activity that enhances gastric motility. This dual action makes it useful for conditions like gastroparesis, whereas drugs like ondansetron target serotonin pathways without affecting gastric emptying.

Metoclopramide Hameln should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use.

Metoclopramide Hameln is supplied for parenteral use and can be given by intramuscular or intravenous injection. The route, rate of infusion, and dilution are determined by the prescribing clinician according to the therapeutic indication and patient-specific factors.

Serious adverse reactions include extrapyramidal symptoms such as acute dystonia, tardive dyskinesia with long‑term use, neuroleptic malignant syndrome, severe depression or suicidal thoughts, anaphylactic reactions, and cardiac arrhythmias. Patients should be monitored closely for any of these events, especially during the initial weeks of therapy.

Metoclopramide Hameln is contraindicated in individuals with known hypersensitivity to metoclopramide or any component of the formulation, in patients with pheochromocytoma, and in those with a history of severe extrapyramidal reactions. Caution is also advised for patients with gastrointestinal obstruction, perforation, or hemorrhage.